VEGFA and age-related macular degeneration: In undifferentiated human ARPE-19 retinal cells mimicking the cells affected by AMD [24], this nutraceutical formulation was also able to reduce the secretion of VEGF by approximately 20% after 24 h of treatment, without affecting cell viability [22].